🔗 Share this article

Given that the US continues making sweeping changes to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines during the pandemic and has zeroed in on possible fatalities after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Program

Public health authorities planned to reveal radical changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with many the global community with insufficient data for benefit. The announcement has been postponed until the next year.

Instead of the top vaccines chief, Høeg is scheduled to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the office this year.

A Shift at the FDA

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for halting some childhood vaccine recommendations in the US so as to align more similar to the Danish model, a country with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, chief of the FDA’s CBER – rather than medication approval.

Concerns Over Expertise

Høeg has no apparent experience in pharmaceutical research, regulation or administrative roles, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in running a major agency. She lacks background in pharmaceutical oversight.”

Previous heads of the center would “understand legal statutes and the research of drug development”, said a former acting FDA commissioner. “Objectively, she lacks the sort of resume that former directors who ran the center have had.”

CDER has an enormous workload at the FDA, Woodcock emphasized.

“Many people just pays attention on the new drug program, but the off-patent medication office authorizes numerous generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and each of these have to be supervised,” Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant management component to the position, which manages in excess of 5,000 employees. “It’s a massive leadership role, if you execute it properly,” Woodcock added.

Response and Contentious Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a spokesperson said that the “inquiries are based on inaccurate assumptions”.

“Her resume is consistent with the duties of her position,” the spokesperson said, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's recently launched priority voucher program, a controversial expedited medication authorization process that reportedly worried her predecessors. “How are these drugs being picked for this fast-track system? Who takes the decisions?” Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he said, “the agency appears to be shifting towards laxer oversight of pharmaceuticals, with the exception of vaccines.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, past, some experts said. She published a analysis using unverified public submissions to assess the rate of myocarditis following Covid immunization. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming government included revising guidelines for novel immunizations and halting “unnecessary” immunizations, she remarked following the vote on a podcast. At the FDA, Høeg has allegedly proposed excluding young men from getting COVID-19 vaccines.

“She is an thorough true believer who commences with her beliefs and works backwards to accommodate the science in a very misleading, untruthful fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|